Loading...
XNAS
ILMN
Market cap28bUSD
Jul 22, Last price  
190.87USD
1D
-0.86%
1Q
52.16%
Jan 2017
53.24%
IPO
901.86%
Name

Illumina Inc

Chart & performance

D1W1MN
XNAS:ILMN chart
P/E
33.97
P/S
6.66
EPS
5.62
Div yield, %
Shrs. gr., 5y
1.06%
Rev. gr., 5y
6.02%
Revenues
4.34b
-0.78%
1,148,516,0001,148,516,0001,421,178,0001,421,178,0001,861,358,0001,861,358,0002,219,762,0002,219,762,0002,398,373,0002,398,373,0002,752,000,0003,333,000,0003,333,000,0003,543,000,0003,239,000,0004,526,000,0004,584,000,0004,504,000,0004,372,000,0004,338,000,000
Net income
850m
P
151,254,000151,254,000125,308,000125,308,000353,351,000353,351,000461,559,000461,559,000462,649,000462,649,000726,000,000826,000,000826,000,0001,002,000,000656,000,000762,000,000-4,404,000,000-1,161,000,000-1,223,000,000850,000,000
CFO
1.08b
+28.91%
291,873,000291,873,000386,421,000386,421,000501,271,000501,271,000659,596,000659,596,000687,238,000687,238,000875,000,0001,142,000,0001,142,000,0001,051,000,0001,080,000,000545,000,000392,000,000478,000,000837,000,0001,079,000,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1998 and headquartered in San Diego, California, Illumina, Inc. delivers cutting-edge sequencing and array technologies crucial for genetic and genomic analysis. The company's comprehensive offerings empower clients across numerous sectors, facilitating the integration of genomic solutions into both research and clinical applications. These span critical fields such as life sciences, oncology, reproductive health, and agriculture. Illumina's product suite encompasses analytical instruments and their associated consumables, complemented by a range of services including genotyping, sequencing, instrument support contracts, development and licensing partnerships, and cancer detection testing. Its extensive customer base comprises genomic research centers, academic bodies, government laboratories, hospitals, pharmaceutical and biotechnology companies, commercial molecular diagnostic labs, and consumer genomics enterprises. The company directly distributes its products across North America, Europe, Latin America, and the Asia-Pacific region, while also leveraging life-science distributors to reach markets in Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
IPO date
Jun 28, 2000
Employees
11,500
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑002021‑002019‑122018‑122018‑122017‑122017‑002016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT